We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
General description of the gene and the encoded protein(s) using information from HGNC and Ensembl, as well as predictions made by the Human Protein Atlas project.
Gene namei
Official gene symbol, which is typically a short form of the gene name, according to HGNC.
All transcripts of all genes have been analyzed regarding the location(s) of corresponding protein based on prediction methods for signal peptides and transmembrane regions.
Genes with at least one transcript predicted to encode a secreted protein, according to prediction methods or to UniProt location data, have been further annotated and classified with the aim to determine if the corresponding protein(s) are secreted or actually retained in intracellular locations or membrane-attached.
Remaining genes, with no transcript predicted to encode a secreted protein, will be assigned the prediction-based location(s).
The annotated location overrules the predicted location, so that a gene encoding a predicted secreted protein that has been annotated as intracellular will have intracellular as the final location.
Intracellular
HUMAN PROTEIN ATLAS INFORMATION
Upregulated in disease (PEA)i
A gene is classified as upregulated in a disease if the average concentration of all samples of that disease is significantly higher (adj P-value<0.005 and NPX difference>=1) than the average concentration of samples of all diseases as measured by PEA . For gender specific diseases the analysis includes only samples corresponding to the same gender from the other diseases.
The blood-based immunoassay category applies to actively secreted proteins and is based on plasma or serum protein concentrations established with enzyme-linked immunosorbent assays, compiled from a literature search. The categories include: detected and not detected, where detection refers to a concentration found in the literature search.
Not analysed since only proteins predicted to be actively secreted to blood is analysed here
Mass spectrometryi
Detection or not of the gene in blood, based on spectral count estimations from a publicly available mass spectrometry-based plasma proteomics data set obtained from the PeptideAtlas.
Detected
Proximity extension assayi
Detection or not of the gene in blood, based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with three visits during two years.
PEA - PROTEIN CONCENTRATIONS IN THE PAN-DISEASE COHORTi
Relative plasma concentrations of proteins in blood from patients having different types of disease measured by proximity extension assay (PEA).
PROTEIN CONCENTRATION IN PLASMA - MASS SPECTROMETRYi
The protein concentration in blood is quantified by mass spectrometry-based plasma proteomics and estimated from spectral counts in a publicly available data set obtained from the PeptideAtlas.
Detected in plasma by mass spectrometry
1.8 µg/L, PeptideAtlas
LONGITUDINAL ANALYSIS OF BLOOD PROTEIN LEVELS (TWO YEARS) - PROXIMITY EXTENSION ASSAYi
The protein profiling results based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with three visits during two years. Protein expression levels are reported as Normalized Protein eXpression (NPX).
Detected in plasma by PEAi
The protein profiling results based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with three visits during two years. Protein expression levels are reported as Normalized Protein eXpression (NPX).
Visit
Detected in plasma by PEAi
The protein profiling results based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with three visits during two years. Protein expression levels are reported as Normalized Protein eXpression (NPX).
The Human Protein Atlas project is funded
